Nadine Carbuccia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4100878/publications.pdf

Version: 2024-02-01

55 papers	3,200 citations	257357 24 h-index	197736 49 g-index
56 all docs	56 docs citations	56 times ranked	4678 citing authors

#	Article	IF	Citations
1	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137.	2.6	10
2	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, 2022, 16, 2057-2070.	2.1	4
3	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of Personalized Medicine, 2022, 12, 655.	1.1	2
4	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. Cancers, 2022, 14, 2275.	1.7	0
5	Overcoming Resistance to Antiâ€“Nectin-4 Antibody-Drug Conjugate. Molecular Cancer Therapeutics, 2022, 21, 1227-1235.	1.9	13
6	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	3.6	24
7	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, 2021, 159, 205-214.	1.3	7
8	3115 â€“ INTEGRATIVE MULTI-OMICS ANALYSIS FOR UNDERSTANDING ACUTE PROMYELOCYTIC LEUKEMIA RESISTANCE: EZH2 ON THE ROAD. Experimental Hematology, 2021, 100, S98.	0.2	0
9	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer, 2020, 59, 30-39.	1.5	17
10	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	2.1	23
11	Genomic characterization of metastatic breast cancers. Nature, 2019, 569, 560-564.	13.7	448
12	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, 2019, 11, 665.	1.7	25
13	High Response to Cetuximab in a Patient With EGFR-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2019, 3, 1-8.	1.5	5
14	Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO Precision Oncology, 2019, 3, 1-9.	1.5	0
15	Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1289-1293.	0.6	4
16	Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genomeâ€wide clonal evolution. Histopathology, 2019, 74, 654-662.	1.6	6
17	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	2
18	Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study. Annals of Oncology, 2018, 29, vi3.	0.6	0

#	Article	IF	Citations
19	RETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for early high-risk HER2-positive breast cancer. Annals of Oncology, 2018, 29, vi1.	0.6	1
20	Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. Blood, 2018, 132, 1401-1401.	0.6	0
21	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica, 2017, 102, e11-e14.	1.7	42
22	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. Blood Cancer Journal, 2017, 7, e594-e594.	2.8	10
23	Epigenetically centered evolution in an example of myeloid malignancy. American Journal of Hematology, 2016, 91, E361-2.	2.0	0
24	Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia, 2016, 30, 966-970.	3.3	31
25	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441.	0.8	11
26	Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219.	0.8	69
27	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292.	2.8	21
28	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843.	1.1	53
29	Concomitant germâ€line <scp>RUNX</scp>1 and acquired <scp>ASXL</scp>1 mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279.	1.1	25
30	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	0.6	220
31	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer, 2012, 51, 743-755.	1.5	139
32	Acute myeloid leukemia with myelodysplasiaâ€related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. American Journal of Hematology, 2012, 87, 659-662.	2.0	67
33	Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e33-e33.	2.8	36
34	Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters, 2010, 1, 883-884.	0.8	7
35	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.	1.1	140
36	Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, 2010, 85, 717-719.	2.0	46

#	Article	IF	Citations
37	A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research, 2010, 34, 254-257.	0.4	35
38	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 365-375.	1.2	199
39	Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 2010, 24, 469-473.	3.3	106
40	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia, 2010, 24, 1539-1541.	3.3	7
41	Mutations of polycombâ€associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800.	1.2	537
42	Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia, 2009, 23, 85-94.	3.3	49
43	Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, 2009, 23, 2183-2186.	3.3	301
44	Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110â€“FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, 2008, 32, 1304-1308.	0.4	24
45	Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder. Cancer Genetics and Cytogenetics, 2007, 173, 154-158.	1.0	24
46	Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genetics and Cytogenetics, 2007, 176, 80-88.	1.0	26
47	Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene, 2006, 25, 1560-1570.	2.6	132
48	Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. British Journal of Haematology, 2004, 125, 601-604.	1.2	24
49	Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene, 2004, 23, 9381-9391.	2.6	44
50	Simple variant t(8;21) acute myeloid leukemias harbor insertions of theAML1 orETO genes. , 1999, 24, 165-171.		28
51	Search for Rearrangements and/or Allelic Loss of the fas/APO-1 Gene in 101 Human Lymphoma. American Journal of Clinical Pathology, 1995, 104, 424-430.	0.4	17
52	Unbalanced translocation t(5;17) in an atypical acute promyelocytic leukemia. Genes Chromosomes and Cancer, 1995, 14, 307-312.	1.5	22
53	Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology, 1995, 27, 235-241.	1.6	57
54	The Expression of FMS, KIT and FLT3 in Hematopoietic Malignancies. Leukemia and Lymphoma, 1994, 13, 223-227.	0.6	35

#	Article	IF	Citations
55	Monensin action on the Golgi complex in perfused rat liver: Evidence against bile salt vesicular transport. Gastroenterology, 1992, 102, 2024-2032.	0.6	21